24 July 2020
Visiongain has launched a new report Microfluidics Market Report 2020-2030: Forecasts by Application (Drug Delivery, Point-of-Care Diagnostics, Pharmaceutical and Biotechnology Research, Clinical Diagnostics, and Others), by Component (Microfluidic Chips, Microfluidic Sensors, Microfluidic Pumps, Microneedles, and Others), by Material (Polymer, Silicone, Glass, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.
Microfluidics is the amalgamation of science and technology employed to investigate microliter to nano-litter quantities of complex fluids such as multi-component mixtures, colloids, cell suspensions, nanoparticle suspensions, biomolecules, bio-fluids such as blood, etc. contained within channels that have diameters on the order of tens to several hundreds of micro-metres. Microfluidics has turn out to be a fundamental instrument facilitating a wide range of measurements and applications from medical diagnostics, molecular biology, genetics, and pharmaceuticals to biophysics, chemistry, nanotechnology, and engineering. The basis apparatus comprises of micro-channels that range from millimetres to centimetres in size implanted in silicon, glass, or polymers. Also, microfluidic devices consist of sensors that have electrical inputs and outputs, as well as photonic sensors.
Cancer is a major health concern in modern societies and the second-leading cause of death for geriatrics. The rising incidence and prevalence of various chronic diseases, coupled with product miniaturization and decentralization of healthcare, are the major factors that are expected to offer significant growth prospects to players operating in point-of-care (POC) devices thereby drive the growth of microfluidics market. The market is also driven by demand for high-throughput screening methodologies, low-volume sample analysis and development of advanced lab-on-a-chip technologies.
Recently the World Health Organization (WHO) announced COVID-19 as pandemic. Thousands of new cases are being tested every day that puts a heavy burden on laboratories. In such cases rapid detection is of paramount importance which can reduce the number of unnecessary visits to the health clinics and will help the health sector to save lives by treating the patients with positive test results. Microfluidics technology is well-suited for point-of-care diagnostics. Microfluidics is associated with handling a tiny amount of fluid in micron-scale channels and chambers. These characteristics along with the high surface to volume ratios allow researchers to handle less amount of samples and reagents with higher efficiencies and generate results faster than conventional methods. Microfluidic PCR chips which have been extensively developed for detecting pathogens such as viruses or bacteria, could offer a viable solution.
The Visiongain report analyst commented “that since the World Health Organization (WHO) announced COVID-19 as pandemic thereby causing many countries to declare emergency state and shutdown public places, diagnostic tools can play a key role in decreasing the spreading rate and controlling the virus. Microfluidics is one such technology that has the potential to offer rapid and affordable point-of-care diagnostic to help in this condition.”
However, several stringent regulatory standards are being made for the implementation of microfluidics in healthcare. The regulatory standards devour too much time for the approval process of microfluidics devices.
The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include UFluidix, Bio-Rad Laboratories Inc., Emulate Inc., Dolomite Microfluidics (Blacktrace Holdings Ltd), Sphere Fluidics Limited, FluIdigm Corporation, Illumina Inc., Micronit Microfluidics, PerkinElmer Inc. and Hesperos, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.
03 December 2020
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.
03 December 2020
Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
03 December 2020
All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.